Buminate Market Report 2026

Buminate Market Overview

• The Buminate market growth in the historic period has been driven by established clinical use of albumin, growth in surgical procedures • Market expansion is supported by increase in trauma cases, rising surgical interventions • Growth Driver: Increased Prevalence Of Liver Diseases As A Key Driver For Buminate Market Growth • North America was the largest region in 2025.

What Is Covered Under Buminate Market?

Buminate refers to a brand name for a human albumin solution, which is a protein derived from human plasma. It is used for medical purposes, primarily to restore or maintain circulating blood volume in patients experiencing shock, burns, trauma, or surgeries. Buminate helps to increase the osmotic pressure of the blood, drawing fluid into the bloodstream to improve circulation and tissue perfusion. The main indication of buminate market is hypoproteinemia, burn treatment, and cardiopulmonary bypass surgery. Hypoproteinemia refers to a condition where a person has low levels of proteins in their blood, especially albumin. This can happen due to malnutrition, liver disease, kidney disease, or severe burns. The various distribution channels include hospital pharmacies, outpatient clinics, and specialty pharmacies and are used by several end-users such as hospitals, clinics, ambulatory care, and home care.

What Is The Buminate Market Growth Forecast?

The growth in the forecast period can be attributed to increase in trauma cases, rising surgical interventions, expansion of icu infrastructure, demand for rapid volume replacement, improved plasma fractionation capacity. Major trends in the forecast period include continued use of albumin in critical care, rising demand in trauma and burn management, expansion of surgical volume support therapies, preference for plasma derived proteins, growth in intensive care admissions.

Global Buminate Market Segmentation

1) By Indication: Hypoproteinemia, Burn Treatment, Cardiopulmonary Bypass Surgery 2) By Distribution Channel: Hospital Pharmacies, Outpatient Clinics, Specialty Pharmacies 3) By End-Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Buminate Market?

The increasing prevalence of liver diseases is expected to propel the growth of the buminate market going forward. Liver diseases refer to a broad range of conditions that impair liver function, including cirrhosis, hepatitis, fatty liver disease, and liver cancer, often caused by factors such as infections, toxins, genetics, or chronic alcohol use. The increasing prevalence of liver diseases is largely driven by unhealthy lifestyle choices and dietary habits as excessive alcohol intake, poor diet, and obesity contribute to liver damage and fat accumulation. Buminate, as a human albumin solution, helps manage liver diseases by restoring and maintaining blood volume and osmotic pressure in patients with conditions such as cirrhosis or liver failure, improving circulation, supporting proper fluid balance, and reducing the risk of complications such as edema and ascites. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in 2023, 17,650 new chronic hepatitis B cases were reported across 44 states and the District of Columbia, representing a prevalence rate of 6.1 cases per 100,000 people. Therefore, the increasing prevalence of liver diseases is driving growth in the buminate industry. The rising healthcare expenditure is expected to propel the growth of the buminate market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Rising healthcare expenditure is due to an ageing population, chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the COVID-19 impact, medical inflation, and income polarization. Buminate benefits from healthcare expenditure as increased investment in healthcare infrastructure and services drives higher demand for effective treatments like Buminate, particularly for managing conditions such as hypoalbuminemia and trauma, leading to broader market adoption, expanded accessibility, and a steady revenue stream for manufacturers and healthcare providers. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in the UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rising healthcare expenditure is driving the growth of the buminate industry. The increasing clinical trials is expected to propel the growth of the buminate market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety, efficacy, and effectiveness of medical treatments, interventions, drugs, or devices. Clinical trials are increasing due to advancements in medical research and technology, the rising incidence of chronic and complex diseases, and an aging global population that demands new treatments. Buminate benefits from clinical trials as they provide valuable data on its safety, efficacy, and potential new applications, which not only support its approval and adoption in various medical settings but also enhance physician confidence, expand its use in treating a broader range of conditions, and ultimately contribute to increased market demand and growth. For instance, in February 2024, according to ClinicalTrials.gov, a US-based government web resource, the clinical trial result publications rose from 4,024 in 2022 to 5,063 in 2023. Therefore, increasing clinical trials is driving the growth of the buminate industry.

Key Players In The Global Buminate Market

Major companies operating in the buminate market are Grifols S.A.

Regional Insights

North America was the largest region in the buminate market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Buminate Market?

The buminate market consists of sales of buminate 25% solution, pre-filled syringes and multi-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Buminate Market Report 2026?

The buminate market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the buminate industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.